Program Guide – ASCO Meeting Program Guide
This abstract shows improvement in transfusion and spleen response with momelotinib in patients with thrombocytopenic myelofibrosis who had prior exposure to JAK inhibitors. Momelotinib was compared to Danazol and had similar toxicities.